Skip to content

Board of Directors

flerie-thomas-people

Thomas Eldered

Chairman of the board

Thomas Eldered

Born 1960. Member of the board since 2011 and chairman of the board since 2023. Member of the audit committee.

Education: M. Sc in Industrial Engineering and Management from Linköping University.

Other relevant experience: Founder of Recipharm AB. Various positions in Pharmacia.

Other ongoing assignments: Board member of T&M Förvaltning AB, T&M Participation AB, Flerie International AB, Åre Mörviken 8:2 AB, Cordivest AB and Pingvinen penningplacering AB.

Previous assignments completed within the past five years: Board member and CEO of Recipharm AB (including various assignments in its subsidiaries), board member of Roar BidCo AB, Flerie Participation AB (dissolved by merger on 18 December 2020), Cobra Biologics AB.

Holdings in the Company: 5,889,002,640 shares through company.

Not independent in relation to the Company and its senior management or in relation to major shareholders.

flerie-cecilia-people-b

Cecilia Edström

Member of the board

Cecilia Edström

Born 1966. Member of the board since 2023. Chairman of the audit committee and member of the remuneration committee.

Education: BSc in Finance and Economics from Stockholm School of Economics and executive development and mentoring program from Ruter Dam.

Other relevant experience: Corporate Finance at SEB, SVP Corporate Relations at Scania, Head of Group Communications at Telia Sonera, and CEO of Bactiguard AB.

Other ongoing assignments: Board member and CEO of ceed konsult AB, board member and acting CFO of A3P Biomedical AB, board member of Nenode Inc, and board member and member of the audit committee of BioArctic AB.

Previous assignments completed within the past five years: Board member and CEO of Bactiguard Holdings AB, deputy CEO and CFO of Bactiguard Holding AB, chairman of the board and CEO of Bactiguard AB, deputy CEO and CFO of Bactiguard AB, board member of Bactiguard International AB, and board member of Nordic Public Affairs.

Holdings in the Company: 2,697,642 shares and 500,000 share options.

Independent both in relation to the Company and its senior management as well as in relation to major shareholders.

flerie-anders-ekblom-people

Anders Ekblom

Member of the board

Anders Ekblom

Born 1954. Member of the board since 2023. Member of the audit committee and chairman of the remuneration committee.

Education: MD, PhD in Physiology, DDS, and Associate Professor from Karolinska Institutet.

Other relevant experience: Two decades at Astra Zeneca as EVP Global Medicines Development, Global Head Clinical Development, and CEO AstraZeneca AB Sweden.

Other ongoing assignments: Chairman of the board of Atrogi AB, Elypta AB, Alligator Bioscience AB, Xspray Pharma and Bostadsrättsföreningen Sportpalatset, board member of AnaMar AB, Nxt Science, Synerkine Pharma and Mereo BioPharma Group Plc.

Previous assignments completed within the past five years: Deputy chairman of the board of Leo Pharma A/S, non-executive board director at the Swedish Research Council.

Holdings in the Company: 2,697,642 shares and 500,000 share options.

Independent both in relation to the Company and its senior management as well as in relation to major shareholders.

flerie-jenni-nordborg-people

Jenni Nordborg

Member of the board

Jenni Nordborg

Born 1970. Member of the board since 2023. Chairman of the remuneration committee and member of the audit committee.

Education: MSc in Chemical Engineering and PhD in Chemistry from Chalmers University of Technology. Executive Leadership Programme from Stockholm School of Economics.

Other relevant experience: Previous National Coordinator for Life Sciences at the Swedish Government Office. Director and head of the health division at Vinnova (Sweden’s innovation agency).

Other ongoing assignments: Director of International Affairs at LIF, the Swedish Pharmaceuticals Trade Association, board member of IHE, Institutet för Hälso- och sjukvårdsekonomi Aktiebolag.

Previous assignments completed within the past five years:

Holdings in the Company: 2,589,736 shares and 444,500 share options.

Independent both in relation to the Company and its senior management as well as in relation to major shareholders.